
The Library
Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus
Tools
Warwick Evidence (Including: Connock, M., Cummins, E., Sutcliffe, P. (Paul), Court, Rachel A., Johnson, Rhona, Grove, Amy L., Kandala, Ngianga-Bakwin, Mohiuddin, Syed and Clarke, Aileen). (2011) Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus. London: National Institute for Health and Clinical Excellence (NICE).
![]()
|
Text
WRAP_Clarke_NICE_Belimumab_56486.pdf - Published Version Download (3875Kb) |
Official URL: http://guidance.nice.org.uk/TA/Wave25/12/Consultat...
Abstract
The manufacturer’s scope encompasses the clinical effectiveness and cost effectiveness of belimumab plus Standard of Care (SoC) relative to SoC alone, for the treatment of adults with active auto-antibody positive Systemic Lupus Erythematosus (SLE) and also for a subgroup of these patients who exhibit signs of high disease activity. According to the manufacturer’s scope and submission the population of greatest interest is the sub-group with high disease activity called the Target population. No subgroup is specified in the National Institute for Health and Clinical Excellence (NICE) scope. The Target population is a subgroup of the proposed licensed population; a decision on the manufacturer’s license application is awaited.
Item Type: | Report | ||||
---|---|---|---|---|---|
Alternative Title: | Evidence review group report commissioned by the National Health Service Research & Development Programme on behalf of the National Institute for Health and Clinical Evidence | ||||
Subjects: | Q Science > QR Microbiology > QR180 Immunology R Medicine > RC Internal medicine |
||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Population, Evidence & Technologies (PET) > Warwick Evidence Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||
Library of Congress Subject Headings (LCSH): | Systemic lupus erythematosus -- Treatment, Monoclonal antibodies | ||||
Publisher: | National Institute for Health and Clinical Excellence (NICE) | ||||
Place of Publication: | London | ||||
Official Date: | 30 September 2011 | ||||
Dates: |
|
||||
Number of Pages: | 166 | ||||
Status: | Peer Reviewed | ||||
Publication Status: | Published | ||||
Access rights to Published version: | Open Access (Creative Commons) | ||||
Date of first compliant deposit: | 1 August 2016 | ||||
Date of first compliant Open Access: | 1 August 2016 | ||||
Funder: | NIHR Health Technology Assessment Programme (Great Britain) | ||||
Grant number: | 10/73/01 (NIHR HTA) |
Request changes or add full text files to a record
Repository staff actions (login required)
![]() |
View Item |
Downloads
Downloads per month over past year